Eli Lilly's Next-Generation Weight Loss Drug Passes Key Obesity Trial
Eli Lilly announced that its next-generation weight loss drug, retatrutide, successfully passed a crucial late-stage trial for obesity. The highest dose led to an average of 28.3% weight loss over 80 weeks and showed potential superiority over existing treatments.
Topics: clinical trial success obesity retatrutide weight loss drug